GILD

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: Gilead is an independent biopharmaceutical company focused on antivirals, antibacterials, and antifungals. Key products include Viread (HIV), AmBisome (antifungal), DaunoXome, and Vistide. The company also holds a collaboration with Hoffmann-La Roche for Tamiflu.

Key Financial Metrics

Margins (Six Months 2002):
- Gross Margin (Product Sales): ~82% (Cost of Goods Sold was 18% of net product sales).
- Operating Margin: ~6.5% ($12.3M operating income / $187.8M revenue).

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 73% year-over-year for the six months ended June 30, 2002 ($187.8M vs. $108.5M). Net product sales rose 90% to $164.5M.
• Profitability Turnaround: The company reported a net income of $15.9M for the six months ended June 30, 2002, compared to a net loss of $54.1M in the same period in 2001.
• Product Mix Shift: Viread sales grew significantly to $71.9M (44% of product sales) in the first half of 2002, compared to minimal sales in 2001. AmBisome sales increased 8% to $87.5M but represented a smaller percentage of total product sales (53%) compared to 93% in 2001.
• Expense Reduction: R&D expenses decreased 32% to $64.4M, driven by the completion of Viread Phase III trials and the divestiture of the oncology program. SG&A expenses increased 58% to $81.4M due to the commercial launch of Viread.
• Cash Flow: Net cash used in operating activities improved significantly to $(21.9M) from $(61.7M) in the prior year, though still negative due to working capital changes.

Guidance, Outlook, and Risks

• Guidance: Management expects full-year 2002 R&D expenses to be $130M–$140M (20–30% lower than 2001). SG&A expenses are expected to be $170M–$180M (35–45% higher than 2001). Cost of goods sold is expected to be approximately 20% of net product sales for the full year.
• Outlook: Viread sales are expected to increase throughout 2002. The company anticipates relying on Viread and AmBisome for a significant portion of operating income.
• Key Risks:
  • Competition: Significant competition in the HIV/AIDS market (Viread) and antifungal market (AmBisome) from major pharmaceutical companies.
  • Regulatory: Risks regarding approval of new products (e.g., adefovir dipivoxil) and potential rejection or limitations by the FDA or foreign agencies.
  • Reimbursement & Pricing: Pressure from government legislation and health care programs to lower drug prices, particularly in the U.S. and Europe.
  • Foreign Currency: A majority of sales are denominated in foreign currencies; a stronger U.S. dollar could reduce reported revenues.
  • Accounts Receivable: Significant past-due receivables ($44.1M) in Greece, Spain, Portugal, and Italy, with $30.2M over 120 days past due.
• Unusual Items:
  • Subsequent Event: In July 2002, the company sold OSI Pharmaceuticals shares for $22.0M, recognizing a non-operating loss of approximately $16.0M to be reflected in the Q3 2002 results.
  • Litigation Settlement: Terminated remaining AmBisome payment obligations to Elan Corporation for $7.3M in June 2002.

Investor Verification Checklist

• Verify the collectibility of the $44.1M in past-due accounts receivable, particularly the $30.2M over 120 days old in Southern European countries.
• Monitor the commercial performance and market penetration of Viread, which now drives nearly half of product sales.
• Assess the impact of the $16.0M non-operating loss from the OSI share sale on Q3 2002 earnings.
• Review the progress of the adefovir dipivoxil licensing agreement with GlaxoSmithKline and potential milestone payments.
• Track the company's ability to maintain gross margins as product mix shifts and foreign exchange rates fluctuate.